{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "term-sheet", "type": "definition", "offset": [66, 76]}], "samples": [{"hash": "e1drxVLXfw0", "uri": "/contracts/e1drxVLXfw0#exclusivity-fee", "label": "Collaboration and License Agreement (Cadence Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "38LnFB1GMxf", "uri": "/contracts/38LnFB1GMxf#exclusivity-fee", "label": "Collaboration and License Agreement (Cadence Pharmaceuticals Inc)", "score": 21.0, "published": true}], "size": 2, "snippet": "means the $200,000 payment made by Strata to Micrologix under the Term Sheet which Micrologix acknowledges it received in two $100,000 payments, the first on June 3, 2004 and the second on July 6, 2004.", "hash": "8b7af58beea7330122ce95ed52aec8bf", "id": 1}, {"snippet_links": [], "samples": [{"hash": "lmtwywu2Uzb", "uri": "http://pdf.secdatabase.com/1453/0001392380-23-000070.pdf", "label": "pdf.secdatabase.com", "score": 19.770495731, "published": false}, {"hash": "ivxypt3bILO", "uri": "https://investors.gevo.com/static-files/97355a83-3d7c-43b6-9961-e6cb8e46fa07", "label": "investors.gevo.com", "score": 11.8350444901, "published": false}], "size": 2, "snippet": "means[*****]. [*****].", "hash": "799c720da3a25eeb9e39398c85fc5531", "id": 2}, {"snippet_links": [{"key": "section-33", "type": "definition", "offset": [32, 43]}], "samples": [{"hash": "jNpnHMpGTTM", "uri": "/contracts/jNpnHMpGTTM#exclusivity-fee", "label": "Material Transfer and Collaboration Agreement (Adagene Inc.)", "score": 32.0499657769, "published": true}, {"hash": "dhKMlPqtIkP", "uri": "/contracts/dhKMlPqtIkP#exclusivity-fee", "label": "Material Transfer and Collaboration Agreement (Adagene Inc.)", "score": 31.8199863107, "published": true}], "size": 2, "snippet": "shall have the meaning given in Section 3.3.", "hash": "d384a15f6e9eb78b9e6679b7dabb1753", "id": 3}, {"snippet_links": [{"key": "section-24", "type": "clause", "offset": [43, 54]}], "samples": [{"hash": "3xEHZOSBtBC", "uri": "/contracts/3xEHZOSBtBC#exclusivity-fee", "label": "Technology Evaluation and Master Development Agreement (Marrone Bio Innovations Inc)", "score": 24.5783709788, "published": true}, {"hash": "8vzTuapyCXf", "uri": "/contracts/8vzTuapyCXf#exclusivity-fee", "label": "Technology Evaluation and Master Development Agreement (Marrone Bio Innovations Inc)", "score": 24.4962354552, "published": true}], "size": 2, "snippet": "shall have the meaning attributed to it in Section 2.4 hereof.", "hash": "c4b6530e0522c3a29926cebf886bf54f", "id": 4}, {"snippet_links": [], "samples": [{"hash": "2qATbIdXxZS", "uri": "/contracts/2qATbIdXxZS#exclusivity-fee", "label": "Agreement and Plan of Merger (Synlogic, Inc.)", "score": 28.6550308008, "published": true}], "size": 1, "snippet": "means Two Million Dollars ($2,000,000).", "hash": "a1be5ac92ba757a6554f48bf39f13f8e", "id": 5}, {"snippet_links": [{"key": "reference-source", "type": "definition", "offset": [59, 75]}], "samples": [{"hash": "dAqdZVDGY4p", "uri": "/contracts/dAqdZVDGY4p#exclusivity-fee", "label": "Partnership Agreement (NEXT-ChemX Corporation.)", "score": 34.234770705, "published": true}], "size": 1, "snippet": "shall have the meaning ascribed to it in Section 1.7Error! Reference source not found..", "hash": "05642a50ffcd4842ce9eac1f58716bd8", "id": 6}, {"snippet_links": [{"key": "section-61", "type": "clause", "offset": [36, 47]}], "samples": [{"hash": "eswNS84NyeQ", "uri": "/contracts/eswNS84NyeQ#exclusivity-fee", "label": "Distribution Agreement", "score": 31.6356115127, "published": true}], "size": 1, "snippet": "has the meaning ascribed thereto in Section 6.1", "hash": "d05d2fa7206c23e615a81a9210f40d4d", "id": 7}, {"snippet_links": [{"key": "in-addition-to-the", "type": "clause", "offset": [0, 18]}, {"key": "payments-in", "type": "clause", "offset": [19, 30]}, {"key": "section-5", "type": "definition", "offset": [31, 40]}, {"key": "an-additional", "type": "clause", "offset": [213, 226]}, {"key": "provided-that", "type": "clause", "offset": [290, 303]}, {"key": "documented-in-writing", "type": "definition", "offset": [323, 344]}, {"key": "acknowledged-by", "type": "definition", "offset": [385, 400]}, {"key": "for-purposes-of-this-agreement", "type": "definition", "offset": [412, 442]}, {"key": "total-cash-receipts", "type": "definition", "offset": [523, 542]}, {"key": "the-licensed-software", "type": "clause", "offset": [661, 682]}, {"key": "projected-sales", "type": "definition", "offset": [829, 844]}, {"key": "board-of-directors", "type": "clause", "offset": [1070, 1088]}, {"key": "based-on", "type": "clause", "offset": [1129, 1137]}, {"key": "as-specified", "type": "clause", "offset": [1158, 1170]}, {"key": "the-foregoing", "type": "definition", "offset": [1174, 1187]}, {"key": "sales-exclusivity", "type": "clause", "offset": [1231, 1248]}, {"key": "budgeted-amount", "type": "definition", "offset": [1317, 1332]}, {"key": "agreement-continues-in-effect", "type": "clause", "offset": [1454, 1483]}, {"key": "will-work", "type": "clause", "offset": [1509, 1518]}, {"key": "the-annual-budget", "type": "clause", "offset": [1540, 1557]}, {"key": "each-calendar-year", "type": "definition", "offset": [1562, 1580]}, {"key": "commencing-with-the", "type": "clause", "offset": [1581, 1600]}, {"key": "prior-to-the", "type": "clause", "offset": [1620, 1632]}, {"key": "the-relevant", "type": "clause", "offset": [1646, 1658]}, {"key": "submission-for-approval", "type": "clause", "offset": [1721, 1744]}, {"key": "table-1", "type": "definition", "offset": [1819, 1826]}, {"key": "calculation-of", "type": "definition", "offset": [1838, 1852]}, {"key": "payments-for", "type": "clause", "offset": [1879, 1891]}, {"key": "the-budget", "type": "definition", "offset": [1934, 1944]}, {"key": "approved-by-the-board", "type": "definition", "offset": [1953, 1974]}, {"key": "not-approved", "type": "definition", "offset": [2029, 2041]}], "samples": [{"hash": "2WtUugHiM08", "uri": "/contracts/2WtUugHiM08#exclusivity-fee", "label": "Software License Agreement (Healthcare Corp of America)", "score": 23.4435318275, "published": true}], "size": 1, "snippet": "in addition to the payments in Section 5(a) above, 340Basics will pay, at the times and in the manner set forth in this Section 5, an Exclusivity Fee in the amount of:\n(i) 5% of 340Basic Script Revenue, plus\n(ii) an additional 2% of 340Basics Script Revenue from clients referred by GENEX, provided that such referrals are documented in writing, via email from GENEX to 340Basics, and acknowledged by 340Basics. For purposes of this Agreement, \u201c340Basics Script Revenue\u201d for a given period shall mean the greater of:\n(iii) total cash receipts of 340Basics and its affiliates during such period that are attributable to sales of 340Basics Products which utilize the Licensed Software, net of reasonable discounts and adjustments actually given; and\n(iv) 70% of the amount specified as \u201c340Basics Script Revenue\u201d, corresponding to projected sales of 340Basics Products which utilize the Licensed Software, net of reasonable discounts and adjustments, for such period in 340Basics\u2019s annual budget (the \u201cAnnual Budget\u201d) in effect for such period, as approved by 340Basics\u2019s Board of Directors. When the Exclusivity Fee is calculated based on total cash receipts as specified in the foregoing clause (i), it shall be referred to as the Sales Exclusivity Fee, and when the Exclusivity Fee is calculated based on the 70% of budgeted amount as specified in the foregoing clause (ii), it shall be referred to as the \u201cMinimum Exclusivity Fee\u201d. For as long as this Agreement continues in effect, 340Basics, HCCA & GENEX will work together to agree on the Annual Budget for each calendar year commencing with the 2015 calendar year prior to the beginning of the relevant calendar year (and in any event prior to such Annual Budget\u2019s submission for approval to HCCA and 340Basic\u2019s Board of Directors). For purposes of illustration, Table 1 provides a calculation of potential Exclusivity Fee payments for the years 2014 (June \u2013 December, based on the budget already approved by the Board) and 2015 (January \u2013 December, based on estimates but not approved by the Board):", "hash": "383611dade7fb74a4fdcab730b2d8127", "id": 8}, {"snippet_links": [], "samples": [{"hash": "jJd7yhMtgHs", "uri": "/contracts/jJd7yhMtgHs#exclusivity-fee", "label": "Master Framework Agreement (Gevo, Inc.)", "score": 34.6043805613, "published": true}], "size": 1, "snippet": "means[*****]. \u200b [*****]. \u200b [*****]. \u200b", "hash": "732560790e67a1fb98589b082b606651", "id": 9}, {"snippet_links": [{"key": "fee-paid", "type": "clause", "offset": [10, 18]}, {"key": "in-exchange", "type": "clause", "offset": [33, 44]}, {"key": "exclusivity-period", "type": "definition", "offset": [52, 70]}, {"key": "the-rights-granted", "type": "clause", "offset": [75, 93]}, {"key": "clause-2", "type": "definition", "offset": [97, 105]}], "samples": [{"hash": "bev6tBqXlpM", "uri": "/contracts/bev6tBqXlpM#exclusivity-fee", "label": "Exclusivity Agreement (Alliance Pharmaceutical Corp)", "score": 18.0, "published": true}], "size": 1, "snippet": "means the fee paid by \u2587\u2587\u2587 to PFC in exchange of the exclusivity period and the rights granted in Clause 2.", "hash": "924a0531b0f0abdd2e9b24eab19d41bc", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYZXhjbHVzaXZpdHktZmVlIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 15, "title": "Exclusivity Fee", "snippet": "means the $200,000 payment made by Strata to Micrologix under the Term Sheet which Micrologix acknowledges it received in two $100,000 payments, the first on June 3, 2004 and the second on July 6, 2004.", "id": "exclusivity-fee", "examples": ["In order for Curis to exercise its right to obtain an Extended Exclusivity Period for a Program Target Profile, there must be, at the time when payment of the Extended <strong>Exclusivity Fee</strong> for such Extended Exclusivity Period is due, an Active Program for such Program Target Profile.", "The first <strong>Exclusivity Fee</strong> payment will be due within [***] of the Effective Date.", "In any such case, Biose shall, within [***] from the effective date of termination, refund to Evelo (i) any Run fees paid by Evelo for any Run scheduled to occur after the effective date of termination, and (ii) a pro rata share of the <strong>Exclusivity Fee</strong> paid under Section 2.3 for the applicable Agreement Year, based on the date of termination in relation to the end of the applicable Agreement Year.", "The second and third <strong>Exclusivity Fee</strong> payments will be due within [***] of the first and second anniversaries of the Effective Date, respectively.", "The <strong>Exclusivity Fee</strong> paid to Argus\u2019 is in consideration of Argus\u2019 obligation to provide the Service exclusively to Enron as set forth in Section 5 and such <strong>Exclusivity Fee</strong> shall be refundable to Enron in the event of a breach of Section 5 by Argus in addition to any other remedies made available to Enron pursuant to Section 14.", "For clarity, if Licensee fails to pay any Target <strong>Exclusivity Fee</strong> when due, the applicable Target Exclusivity shall automatically expire (which expiration shall be TeneoBio\u2019s sole remedy, and Licensee\u2019s sole liability, for such failure).", "On the Commencement Date, Enron shall pay Argus a fee of $40,000.00 (the \u201c<strong>Exclusivity Fee</strong>\u201d) for the Service, such <strong>Exclusivity Fee</strong> to be due and payable at the offices of Argus set forth herein.", "The Company agrees to use the proceeds from the Initial <strong>Exclusivity Fee</strong> first, to pay expenses associated with the Project and thereafter for general working capital purposes.", "If the Parties are unable to agree to an adjustment to the Milestones or other aspects of the Joint Development Plan through the procedures set forth in Section 13.1 and Stepan does not elect to pay the <strong>Exclusivity Fee</strong> in accordance with the foregoing, ERS may terminate the Joint Development Plan as set forth in Section 11.3.", "Fujisawa Receptor Assay; Maintenance Fee; <strong>Exclusivity Fee</strong> 10 Article V."], "related": [["license-fee", "License Fee", "License Fee"], ["royalty-fee", "Royalty Fee", "Royalty Fee"], ["sublicense-fees", "Sublicense Fees", "Sublicense Fees"], ["license-fees", "License Fees", "License Fees"], ["exclusivity-period", "Exclusivity Period", "Exclusivity Period"]], "related_snippets": [], "updated": "2025-07-06T21:58:41+00:00"}, "json": true, "cursor": ""}}